# US 2019/0315755 A1 · Bicyclic heterocyclic derivatives as mnk1 and mnk2 modulators and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0315755 A1
- Document ID: US20190315755A1
- Status: Published application
- Kind: A1
- Application number: 16/432,469
- Filed: 2019-06-05
- Published: 2019-10-17
- Earliest claimed: 2012-03-30
- Assignees: Agency for Science, Technology and Research
- Applicants: Agency for Science, Technology, and Research
- Inventors: Kassoum Nacro; Athisayamani Jeyaraj Duraiswamy; Lohitha Rao Chennamaneni
- Web page: https://patentgrep.com/patent/US20190315755A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61K 31/4184: condensed with carbocyclic rings, e.g. benzimidazoles
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/5025: ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/551: having two nitrogen atoms, e.g. dilazep
- A61K 31/553: having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07D 235/06: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D 471/04: Ortho-condensed systems
- C07D 471/10: Spiro-condensed systems
- C07D 491/107: with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to certain compounds (e.g., imidazopyrazine, imidazopyridine, imidazopyridazine and imidazpyrimidine compounds) that act as inhibitors of the MAP kinase interacting kinases MNK2a, MNK2b, MNK1a, and MNK1b. The present invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the preparation of a medicament for the prophylaxis and treatment of diseases (e.g., proliferative diseases (e.g., cancer), inflammatory diseases, Alzheimer's disease), as well as methods of treating these diseases.

## Claims

### Claim 1

A compound of Formula (Ib-i):
or a pharmaceutically acceptable salt thereof, wherein:
X1, X2, and X3 are independently N or C;
X4 and X5 are independently N or CR4;
wherein at least one of X1, X2, X3, X4, and X5 is N;
X7 is N or CH;
X8 is N or CH;
is a single or double bond, as valency allows;
R1 is —C(O)R, wherein R is an optionally substituted heterocyclyl;
R2, R3, R6, and R7 are independently H, —F, —Cl, —CN, —CH3, —CF3, —CHF2, —C(O)NH2, —OH, —OC1-4alkyl, or —OCF3; or R6 and R7 are taken together to form a 5-6 membered fused heterocyclyl or heteroaryl; and
each R4 is independently hydrogen or C1-6 alkyl.

### Claim 2 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein X2 is C.

### Claim 3 (depends on 2)

The compound of claim 2, or a pharmaceutically acceptable salt thereof, wherein R1 is —C(O)R, wherein:
R is of the formula:
each Rc is independently optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
each Rd is independently optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, —CORc, S(O)Rc, S(O)2Rc, optionally substituted alkylaryl, or optionally substituted aryl;
each Re is independently hydrogen, halo, —OH, —ORc, —NH2, —NHRc, —NHSO2Rc, —NRfSO2Rc, —NRcRf, —CN, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, —CORc, or —NHCORc;
each Rf is independently —H or C1-6 alkyl;
each Rg is independently hydrogen, halo, —OH, —ORc, —NH2, —NHRc, —NHSO2Rc, —NRfSO2Rc, —NRcRf, —CN, optionally substituted alkyl, optionally substituted alkenyl, optionally
substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, —CORc, or —NHCORc; and
n is 1, or 2.

### Claim 4 (depends on 3)

The compound of claim 3, or a pharmaceutically acceptable salt thereof, wherein R1 is —C(O)R, wherein R is one of the following:

### Claim 5 (depends on 3)

The compound of claim 3, or a pharmaceutically acceptable salt thereof, wherein R is of the formula:

### Claim 6 (depends on 3)

The compound of claim 3, or a pharmaceutically acceptable salt thereof, wherein R is of the formula:

### Claim 7 (depends on 2)

The compound of claim 2, or a pharmaceutically acceptable salt thereof, wherein both R2 and R3 are hydrogen.

### Claim 8 (depends on 2)

The compound of claim 2, or a pharmaceutically acceptable salt thereof, wherein R6 is —H.

### Claim 9 (depends on 2)

The compound of claim 2, or a pharmaceutically acceptable salt thereof, wherein R7 is —F, —Cl, or —CN.

### Claim 10 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein X3 is N.

### Claim 11 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein X7 and X8 are each CH.

### Claim 12 (depends on 1)

The compound of claim 1, wherein the compound is of Formula (Ib-ii):
or a pharmaceutically acceptable salt thereof.

### Claim 13 (depends on 1)

The compound of claim 1, wherein the compound is of Formula (IIa), (IIIa), (IVa), (Va), (VIa), or (VIIa):
or a pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

### Claim 15 (depends on 1)

A method of treating an MNK1-related disorder or MNK2-related disorder in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 15)

The method of claim 15, wherein the MNK1-related disorder or MNK2-related disorder is cancer, an inflammatory condition, Alzheimer's disease, or a metabolic disorder.

### Claim 17 (depends on 15)

The method of claim 15, wherein the disorder is a hematological cancer or solid tumor.

### Claim 18 (depends on 15)

The method of claim 15, wherein the compound is administered in combination with an additional therapeutic agent.

### Claim 19 (depends on 1)

A kit comprising the compound of claim 1, or a pharmaceutically acceptable salt thereof, and instructions for administering the compound or the composition to a subject.

### Claim 20

A compound of formula:
or a pharmaceutically acceptable salt thereof.
